Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Director | June 15, 2026 | June 15, 2026 |
| Erasca, Inc.ERAS · Entity 3796 | Director · Chairman & CEO · 10% owner | January 29, 2026 | January 30, 2026 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date June 15, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2036-06-14 | Direct | 48,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 48,000 · Balance 48,000 F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.
Erasca, Inc.
Report date January 29, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.31 · Expires 2036-01-29 | Direct | 2,000,000 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 2,000,000 · Balance 2,000,000 F1: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ignyta, Inc.
Report date February 08, 2018 · Filed February 12, 2018
Section 16 reporting ended · disclosed 2018-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 1
1 source rowRow 1 · 2018-02-08 · Disposition to issuer · Disposed 179,661 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). |
| Common StockSEC Table I · non-derivative | IndirectBy City Hill Venture Partners I, LLC | 0 |
Reported balance
After 2018-02-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-02-08 · Disposition to issuer · Disposed 3,350,000 · Balance 0 F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). F2: The Reporting Person is the Manager of City Hill Ventures, LLC, which is the Manager of City Hill Ventures Partners I, LLC, and as such the Reporting Person and City Hill Ventures, LLC have the power to vote or dispose of the securities held of record by the Reporting Person and may be deemed to beneficially own those securities. The Reporting Person disclaims beneficial ownership of the securities held of record by the City Hill Venture Partners I, LLC except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-16 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-08 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.58 · Expires 2015-01-07 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-08 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2027-01-04 | Direct | 0 |
Reported balance
After 2018-02-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-02-08 · Disposition to issuer · Disposed 120,000 · Balance 0 F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger").
F2: The Reporting Person is the Manager of City Hill Ventures, LLC, which is the Manager of City Hill Ventures Partners I, LLC, and as such the Reporting Person and City Hill Ventures, LLC have the power to vote or dispose of the securities held of record by the Reporting Person and may be deemed to beneficially own those securities. The Reporting Person disclaims beneficial ownership of the securities held of record by the City Hill Venture Partners I, LLC except to the extent of his pecuniary interest therein.
F3: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 15, 2026 23:36 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001193125-26-271465 · ownership.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:28 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0001283290-26-000002 · form4-06102026_080618.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-06-07 F1 · derivative.exercise_date: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| January 29, 2026 Filed Jan 30, 2026 14:05 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $10.31 | $0.00 |
DisclosureSEC source: 0001193125-26-030626 · ownership.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:17 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.67 | $0.00 |
DisclosureSEC source: 0001283290-25-000005 · form4-09242025_080917.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 21:13 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-25-089077 · ownership.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-22 F1 · derivative.exercise_date: The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionSeries B Preferred Stock · Derivative | 2,231,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 5 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 270,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F3 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F3 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F3 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionSeries A Preferred Stock · Derivative | 363,703 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 4 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 37,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F1 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F1 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionCommon Stock | 270,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · nonDerivative · entry 2 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · City Hill, LLC Disclosed balance after: 307,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionCommon Stock | 37,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · City Hill, LLC Disclosed balance after: 37,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F2 · ownership.nature: These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 14:15 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 2,500,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-25-014192 · ownership.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2025, subject to the Reporting Person's continuous service to the issuer on each such vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 8 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,086 Underlying: Common Stock · 9,086 shares Expires 2034-12-08 F4 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025. F7 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,704 | Not disclosed Strike: $17.74 | Not disclosed |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 7 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,704 shares Expires 2033-03-08 F4 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025. F6 · price: This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. F5 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:37 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 5,704 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001415889-25-002957 · form4-02042025_090248.xml · derivative · entry 6 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,704 Underlying: Common Stock · 5,704 shares Expires 2033-03-08 F4 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025. F6 · price: This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. F5 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 23:49 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (Right to Buy) · Derivative | 6,610 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000950170-24-075800 · ownership.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,610 Underlying: Common Stock · 6,610 shares Expires 2034-06-19 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2024 Incentive Award Plan. The stock option vests in 36 substantially equal monthly installments beginning on the first monthly anniversary of June 20, 2024, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 12:47 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 632,759 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-24-005924 · doc4.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,759 Underlying: Common Stock · 632,759 shares Expires 2034-06-19 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on June 20, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionSeries C Convertible Preferred Stock · Derivative | 7,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-041843 · ownership.xml · derivative · entry 5 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 7,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionSeries B Convertible Preferred Stock · Derivative | 5,128 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-041843 · ownership.xml · derivative · entry 4 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 5,128 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionSeries A Convertible Preferred Stock · Derivative | 512,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-041843 · ownership.xml · derivative · entry 3 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 512,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | ConversionCommon Stock | 525,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-041843 · ownership.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By City Hill, LLC Disclosed balance after: 550,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 13,219 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038705 · ownership.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,219 Underlying: Common Stock · 13,219 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 23:54 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001209191-24-002968 · doc4.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2034-02-04 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 00:41 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 278,150 | $1.72 | $478,418.00 |
DisclosureSEC source: 0001209191-23-057681 · doc4.xml · nonDerivative · entry 2 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By City Hill, LLC Disclosed balance after: 12,899,360 F1 · balance_after: Includes purchases made on December 5, 2023, and December 6, 2023 that are reported on this Form 4. F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 00:41 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 721,850 | $1.69 | $1,217,760.95 |
DisclosureSEC source: 0001209191-23-057681 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By City Hill, LLC Disclosed balance after: 12,899,360 F1 · balance_after: Includes purchases made on December 5, 2023, and December 6, 2023 that are reported on this Form 4. F2 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 12:00 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 1,000,000 | $2.03 | $2,026,000.00 |
DisclosureSEC source: 0001209191-23-052403 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Jonathan E. Lim and Conyee T. lim Family Trust, dated April 28, 2005 Disclosed balance after: 19,456,216 F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 00:54 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 100,000 | $2.75 | $275,000.00 |
DisclosureSEC source: 0001209191-23-035590 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 18,396,216 F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 01:24 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 100,000 | $2.84 | $284,000.00 |
DisclosureSEC source: 0001209191-23-021458 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 18,296,216 F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 13:55 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006482 · doc4.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 10, 2023 Filed Jan 10, 2023 21:46 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 60,000 | $3.86 | $231,420.00 |
DisclosureSEC source: 0001209191-23-002802 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 20,256,222 F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| December 14, 2022 Filed Dec 15, 2022 16:53 UTC | Erasca, Inc. ERAS · Entity 3796 | PurchaseCommon Stock | 40,000 | $4.99 | $199,600.00 |
DisclosureSEC source: 0001209191-22-061352 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 20,196,222 F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| November 30, 2022 Filed Feb 16, 2023 01:55 UTC | Erasca, Inc. ERAS · Entity 3796 | GiftCommon Stock | 2,000,006 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005182 · doc5.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 18,196,216 F1 · kind: Transfer of shares to a trust of which the children of the Reporting Person and his spouse are beneficiaries. F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:51 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (Right to Buy) · Derivative | 791,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-22-007062 · doc4.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,000 Underlying: Common Stock · 791,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:58 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries B-2 Preferred Stock · Derivative | 112,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 6 Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner Lim Conyee T. · CIK 0001872346 · 10% owner City Hill, LLC · CIK 0001872305 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 93,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:58 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries B-1 Preferred Stock · Derivative | 336,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 5 Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner Lim Conyee T. · CIK 0001872346 · 10% owner City Hill, LLC · CIK 0001872305 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 280,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:58 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries A Preferred Stock · Derivative | 6,081,233 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 4 Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner Lim Conyee T. · CIK 0001872346 · 10% owner City Hill, LLC · CIK 0001872305 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By City Hill, LLC Disclosed balance after: 0 Underlying: Common Stock · 5,067,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:58 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionSeries A Preferred Stock · Derivative | 6,162,468 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-029085 · doc4.xml · derivative · entry 3 Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner Lim Conyee T. · CIK 0001872346 · 10% owner City Hill, LLC · CIK 0001872305 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 0 Underlying: Common Stock · 5,135,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:58 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionCommon Stock | 5,441,027 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029085 · doc4.xml · nonDerivative · entry 2 Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner Lim Conyee T. · CIK 0001872346 · 10% owner City Hill, LLC · CIK 0001872305 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By City Hill, LLC Disclosed balance after: 11,899,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F3 · ownership.nature: Consists of shares held directly by City Hill, LLC ("City Hill"). Jonathan E. Lim, M.D. serves as the managing partner of City Hill. Dr. Lim exercises voting and dispositive control over the securities held by City Hill and is therefore deemed to be a beneficial owner of securities owned by City Hill. Dr. Lim disclaims beneficial ownership of the reported securities held by City Hill, except to the extent of his pecuniary interest therein. Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 00:58 UTC | Erasca, Inc. ERAS · Entity 3796 | ConversionCommon Stock | 5,135,390 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-029085 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · See Remarks · 10% owner Lim Conyee T. · CIK 0001872346 · 10% owner City Hill, LLC · CIK 0001872305 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005 Disclosed balance after: 20,156,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 1.2-for-1 share, immediately prior to the consummation of the Issuer's initial public offering. F2 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of (i) Jonathan E. Lim, M.D. and (ii) Conyee T. Lim, M.D., who are co-trustees of the Jonathan E. Lim and Conyee T. Lim Family Trust, dated April 28, 2005. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:33 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-18-009148 · doc4.xml · derivative · entry 5 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2027-01-04 F3 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:33 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.58 | $0.00 |
DisclosureSEC source: 0001209191-18-009148 · doc4.xml · derivative · entry 4 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2015-01-07 F3 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:33 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009148 · doc4.xml · derivative · entry 3 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2023-12-16 F3 · derivative.exercise_date: In connection with the Merger described in footnote (1), this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:33 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerCommon Stock | 3,350,000 | $27.00 | $90,450,000.00 |
DisclosureSEC source: 0001209191-18-009148 · doc4.xml · nonDerivative · entry 2 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By City Hill Venture Partners I, LLC Disclosed balance after: 0 F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). F2 · ownership.nature: The Reporting Person is the Manager of City Hill Ventures, LLC, which is the Manager of City Hill Ventures Partners I, LLC, and as such the Reporting Person and City Hill Ventures, LLC have the power to vote or dispose of the securities held of record by the Reporting Person and may be deemed to beneficially own those securities. The Reporting Person disclaims beneficial ownership of the securities held of record by the City Hill Venture Partners I, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:33 UTC | Ignyta, Inc. RXDX · Entity 169521 | Disposition to issuerCommon Stock | 179,661 | $27.00 | $4,850,847.00 |
DisclosureSEC source: 0001209191-18-009148 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). Read SEC document |
| December 26, 2017 Filed Dec 29, 2017 02:34 UTC | Ignyta, Inc. RXDX · Entity 169521 | Tax withholdingCommon Stock | 19,006 | $26.70 | $507,460.20 |
DisclosureSEC source: 0000899243-17-029701 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,661 Read SEC document |
| December 22, 2017 Filed Dec 23, 2017 02:47 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantCommon Stock | 68,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-067162 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,667 F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date. Read SEC document |
| December 22, 2017 Filed Dec 28, 2017 00:49 UTC Amendment | Ignyta, Inc. RXDX · Entity 169521 | GrantCommon Stock | 68,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029643 · doc4a.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,667 F1 · shares: Represents the grant of restricted stock units to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units will vest as to 25% of the shares underlying each award on each anniversary of the Grant Date, subject to the Reporting Person's continues service with the Company through the vesting date. Read SEC document |
| February 13, 2017 Filed Mar 11, 2017 01:05 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,945 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-17-019996 · doc4.xml · derivative · entry 3 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,945 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2017 Filed Mar 11, 2017 01:05 UTC | Ignyta, Inc. RXDX · Entity 169521 | Exercise / conversionCommon Stock | 6,945 | $0.60 | $4,167.00 |
DisclosureSEC source: 0001209191-17-019996 · doc4.xml · nonDerivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 23:51 UTC | Ignyta, Inc. RXDX · Entity 169521 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002767 · doc4.xml · derivative · entry 1 Lim Jonathan E · CIK 0001283290 · Director · President, CEO & Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The option is exercisable as it vests. 25% of the shares subject to the option vest on January 5, 2018, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.